Paper7689439
The future of the quinolones.
Andriole VT. Drugs, 1993. Cited by 19 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The future of the quinolones. Papers, record 7689439. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7689439
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Infective Agents | Major topic |
| Technology, Pharmaceutical | Major topic |
| Fluoroquinolones | |
| Humans |
Source PubMed
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1,316,228 | Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity. | Cancer Res | 1992 | https://conductscience.org/library/papers/1316228 | PubMed |
| 2 | 1,320,366 | In vitro activities of five quinolones against Chlamydia pneumoniae. | Antimicrob Agents Chemother | 1992 | https://conductscience.org/library/papers/1320366 | PubMed |
| 3 | 1,329,621 | Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci. | Antimicrob Agents Chemother | 1992 | https://conductscience.org/library/papers/1329621 | PubMed |
| 4 | 1,650,698 | Mode of action of the new quinolones: new data. | Eur J Clin Microbiol Infect Dis | 1991 | https://conductscience.org/library/papers/1650698 | PubMed |
| 5 | 1,622,183 | Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro. | Antimicrob Agents Chemother | 1992 | https://conductscience.org/library/papers/1622183 | PubMed |
| 6 | 186,775 | DNA gyrase: an enzyme that introduces superhelical turns into DNA. | Proc Natl Acad Sci U S A | 1976 | https://conductscience.org/library/papers/186775 | PubMed |
| 7 | 337,300 | Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. | Proc Natl Acad Sci U S A | 1977 | https://conductscience.org/library/papers/337300 | PubMed |
| 8 | 4,279,300 | Interactions between twisted DNAs and enzymes: the effects of superhelical turns. | J Mol Biol | 1974 | https://conductscience.org/library/papers/4279300 | PubMed |
| 9 | 1,323,952 | Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group. | Antimicrob Agents Chemother | 1992 | https://conductscience.org/library/papers/1323952 | PubMed |
| 10 | 347,446 | Purification of subunits of Escherichia coli DNA gyrase and reconstitution of enzymatic activity. | Proc Natl Acad Sci U S A | 1978 | https://conductscience.org/library/papers/347446 | PubMed |
| 11 | 1,329,642 | Antimicrobial activities of two investigational fluoroquinolones (CI-960 and E4695) against over 100 Legionella sp. isolates. | Antimicrob Agents Chemother | 1992 | https://conductscience.org/library/papers/1329642 | PubMed |
| 12 | 358,918 | Mode of incomplete cross-resistance among pipemidic, piromidic, and nalidixic acids. | Antimicrob Agents Chemother | 1978 | https://conductscience.org/library/papers/358918 | PubMed |
| 13 | 14,056,431 | 1,8-NAPHTHYRIDINE DERIVATIVES. A NEW CLASS OF CHEMOTHERAPEUTIC AGENTS. | J Med Pharm Chem | 1962 | https://conductscience.org/library/papers/14056431 | PubMed |
| 14 | 2,992,360 | DNA topoisomerases. | Annu Rev Biochem | 1985 | https://conductscience.org/library/papers/2992360 | PubMed |
| 15 | 1,330,419 | In vitro activity of CP-74667 compared with four other fluoroquinolones. | Diagn Microbiol Infect Dis | 1992 | https://conductscience.org/library/papers/1330419 | PubMed |
| 16 | 200,930 | Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. | Proc Natl Acad Sci U S A | 1977 | https://conductscience.org/library/papers/200930 | PubMed |
| 17 | 1,416,832 | Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae. | Antimicrob Agents Chemother | 1992 | https://conductscience.org/library/papers/1416832 | PubMed |
| 18 | 772,446 | Nalidixic acid and bacterial chromosome replication. | Nature | 1976 | https://conductscience.org/library/papers/772446 | PubMed |
| 19 | 1,864,295 | Use of quinolones in treatment of prostatitis and lower urinary tract infections. | Eur J Clin Microbiol Infect Dis | 1991 | https://conductscience.org/library/papers/1864295 | PubMed |
| 20 | 1,650,363 | Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. | J Biol Chem | 1991 | https://conductscience.org/library/papers/1650363 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37,166,011 | A CcdB toxin-derived peptide acts as a broad-spectrum antibacterial therapeutic in infected mice. | EMBO Rep | 2023 | https://conductscience.org/library/papers/37166011 | PubMed |
| 24,705,262 | Sequencing of bacterial genomes: principles and insights into pathogenesis and development of antibiotics. | Genes (Basel) | 2013 | https://conductscience.org/library/papers/24705262 | PubMed |
| 23,119,344 | Sparfloxacin: An Overview of Its Efficacy in ENT Infections. | Indian J Otolaryngol Head Neck Surg | 1997 | https://conductscience.org/library/papers/23119344 | PubMed |
| 22,346,384 | The new fluoroquinolones: A critical review. | Can J Infect Dis | 1999 | https://conductscience.org/library/papers/22346384 | PubMed |
| 17,160,049 | Antibacterial discovery and development--the failure of success? | Nat Biotechnol | 2006 | https://conductscience.org/library/papers/17160049 | PubMed |
| 11,790,155 | A critical review of the fluoroquinolones: focus on respiratory infections. | Drugs | 2002 | https://conductscience.org/library/papers/11790155 | PubMed |
| 10,553,697 | The future of the quinolones. | Drugs | 1999 | https://conductscience.org/library/papers/10553697 | PubMed |
| 9,210,692 | In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. | Antimicrob Agents Chemother | 1997 | https://conductscience.org/library/papers/9210692 | PubMed |
| 8,974,081 | Inhibition of rat parotid gland growth response induced by chronic isoproterenol following treatment with quinolone antibiotics. | Mol Cell Biochem | 1996 | https://conductscience.org/library/papers/8974081 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7689439
GET https://conductscience.org/api/papers/v1/7689439/references?page=2